Cargando…
482. Long-Term Outcomes of Coronavirus disease 2019 and Risk Factors for Prolonged SARS-CoV-2 Infection in Lymphoma Patients: Multicenter, Retrospective Cohort Study
BACKGROUND: In lymphoma patients, SARS-CoV-2 is often detected continuously even after a sufficient amount of time has passed since being confirmed with COVID-19. We aim to describe the long-term outcomes of COVID-19 and identify the risk factors for prolonged SARS-CoV-2 infection in lymphoma patien...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676920/ http://dx.doi.org/10.1093/ofid/ofad500.552 |
_version_ | 1785150007696949248 |
---|---|
author | Lee, Jung Ah Han, Min Ahn, Sangmin Lee, Yongseop Yeom, Joon-sup Choi, Jun Yong Ku, Nam Su Jeong, Su Jin Kim, Jung Ho Kim, Jin Seok Chung, Haerim Cho, Hyunsoo Kim, Yu Ri Ahn, Jin Young |
author_facet | Lee, Jung Ah Han, Min Ahn, Sangmin Lee, Yongseop Yeom, Joon-sup Choi, Jun Yong Ku, Nam Su Jeong, Su Jin Kim, Jung Ho Kim, Jin Seok Chung, Haerim Cho, Hyunsoo Kim, Yu Ri Ahn, Jin Young |
author_sort | Lee, Jung Ah |
collection | PubMed |
description | BACKGROUND: In lymphoma patients, SARS-CoV-2 is often detected continuously even after a sufficient amount of time has passed since being confirmed with COVID-19. We aim to describe the long-term outcomes of COVID-19 and identify the risk factors for prolonged SARS-CoV-2 infection in lymphoma patients. METHODS: A multicenter retrospective cohort study was conducted on patients receiving treatment for lymphoma at three tertiary hospitals in South Korea who were quarantined after being diagnosed with COVID-19 by polymerase chain reaction (PCR) testing or antigen test from August 2021 to July 2022. Prolonged COVID-19 is defined as a case where PCR remains positive even after 30 days of COVID-19 confirmation or when COVID-19 pneumonia occurs or worsens after 30 days of COVID-19 confirmation. RESULTS: A total of 77 lymphoma patients with COVID-19 were studied. Among them, 24 (31%) patients were classified as prolonged COVID-19 and seven patients (9.1%) died within 90 days after the diagnosis of COVID-19. (Table 1) Prolonged COVID-19 was more frequently identified in follicular lymphoma patients with a history of bendamustine and rituximab (BR) treatment (22.6% vs. 50.0%, p=0.016), especially those who maintained rituximab maintenance treatment after BR treatment (11.3% vs. 37.5%, p=0.012). (Table 2) At the time of initial COVID-19 diagnosis, the 'prolonged COVID-19 group' did not show clinically significant differences compared to the non-prolonged COVID group. (Table 3) Multivariable analysis showed that BR treatment followed by rituximab maintenance is one of the risk factors for persistent PCR positivity (OR 3.375, 95% CI 1.104-10.317, p=0.033), delayed or persistent pneumonia (OR 8.833, 95% CI 2.527-30.879, p=0.001), and COVID-19 related admission after quarantine period (OR 11.1, 95% CI 2.758-44.678, p=0.001). Prolonged COVID-19 had an impact on the delay of cancer treatment but did not increase the risk of 90-day or 180-day mortality significantly. (Table 4) [Figure: see text] [Figure: see text] [Figure: see text] CONCLUSION: In this study, patients with lymphoma who have received certain treatments may have a higher risk of developing COVID-19 pneumonia due to prolonged infection. Further study is needed to understand the immune responses in this patient group and find treatment methods. [Figure: see text] DISCLOSURES: All Authors: No reported disclosures |
format | Online Article Text |
id | pubmed-10676920 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106769202023-11-27 482. Long-Term Outcomes of Coronavirus disease 2019 and Risk Factors for Prolonged SARS-CoV-2 Infection in Lymphoma Patients: Multicenter, Retrospective Cohort Study Lee, Jung Ah Han, Min Ahn, Sangmin Lee, Yongseop Yeom, Joon-sup Choi, Jun Yong Ku, Nam Su Jeong, Su Jin Kim, Jung Ho Kim, Jin Seok Chung, Haerim Cho, Hyunsoo Kim, Yu Ri Ahn, Jin Young Open Forum Infect Dis Abstract BACKGROUND: In lymphoma patients, SARS-CoV-2 is often detected continuously even after a sufficient amount of time has passed since being confirmed with COVID-19. We aim to describe the long-term outcomes of COVID-19 and identify the risk factors for prolonged SARS-CoV-2 infection in lymphoma patients. METHODS: A multicenter retrospective cohort study was conducted on patients receiving treatment for lymphoma at three tertiary hospitals in South Korea who were quarantined after being diagnosed with COVID-19 by polymerase chain reaction (PCR) testing or antigen test from August 2021 to July 2022. Prolonged COVID-19 is defined as a case where PCR remains positive even after 30 days of COVID-19 confirmation or when COVID-19 pneumonia occurs or worsens after 30 days of COVID-19 confirmation. RESULTS: A total of 77 lymphoma patients with COVID-19 were studied. Among them, 24 (31%) patients were classified as prolonged COVID-19 and seven patients (9.1%) died within 90 days after the diagnosis of COVID-19. (Table 1) Prolonged COVID-19 was more frequently identified in follicular lymphoma patients with a history of bendamustine and rituximab (BR) treatment (22.6% vs. 50.0%, p=0.016), especially those who maintained rituximab maintenance treatment after BR treatment (11.3% vs. 37.5%, p=0.012). (Table 2) At the time of initial COVID-19 diagnosis, the 'prolonged COVID-19 group' did not show clinically significant differences compared to the non-prolonged COVID group. (Table 3) Multivariable analysis showed that BR treatment followed by rituximab maintenance is one of the risk factors for persistent PCR positivity (OR 3.375, 95% CI 1.104-10.317, p=0.033), delayed or persistent pneumonia (OR 8.833, 95% CI 2.527-30.879, p=0.001), and COVID-19 related admission after quarantine period (OR 11.1, 95% CI 2.758-44.678, p=0.001). Prolonged COVID-19 had an impact on the delay of cancer treatment but did not increase the risk of 90-day or 180-day mortality significantly. (Table 4) [Figure: see text] [Figure: see text] [Figure: see text] CONCLUSION: In this study, patients with lymphoma who have received certain treatments may have a higher risk of developing COVID-19 pneumonia due to prolonged infection. Further study is needed to understand the immune responses in this patient group and find treatment methods. [Figure: see text] DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10676920/ http://dx.doi.org/10.1093/ofid/ofad500.552 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Lee, Jung Ah Han, Min Ahn, Sangmin Lee, Yongseop Yeom, Joon-sup Choi, Jun Yong Ku, Nam Su Jeong, Su Jin Kim, Jung Ho Kim, Jin Seok Chung, Haerim Cho, Hyunsoo Kim, Yu Ri Ahn, Jin Young 482. Long-Term Outcomes of Coronavirus disease 2019 and Risk Factors for Prolonged SARS-CoV-2 Infection in Lymphoma Patients: Multicenter, Retrospective Cohort Study |
title | 482. Long-Term Outcomes of Coronavirus disease 2019 and Risk Factors for Prolonged SARS-CoV-2 Infection in Lymphoma Patients: Multicenter, Retrospective Cohort Study |
title_full | 482. Long-Term Outcomes of Coronavirus disease 2019 and Risk Factors for Prolonged SARS-CoV-2 Infection in Lymphoma Patients: Multicenter, Retrospective Cohort Study |
title_fullStr | 482. Long-Term Outcomes of Coronavirus disease 2019 and Risk Factors for Prolonged SARS-CoV-2 Infection in Lymphoma Patients: Multicenter, Retrospective Cohort Study |
title_full_unstemmed | 482. Long-Term Outcomes of Coronavirus disease 2019 and Risk Factors for Prolonged SARS-CoV-2 Infection in Lymphoma Patients: Multicenter, Retrospective Cohort Study |
title_short | 482. Long-Term Outcomes of Coronavirus disease 2019 and Risk Factors for Prolonged SARS-CoV-2 Infection in Lymphoma Patients: Multicenter, Retrospective Cohort Study |
title_sort | 482. long-term outcomes of coronavirus disease 2019 and risk factors for prolonged sars-cov-2 infection in lymphoma patients: multicenter, retrospective cohort study |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676920/ http://dx.doi.org/10.1093/ofid/ofad500.552 |
work_keys_str_mv | AT leejungah 482longtermoutcomesofcoronavirusdisease2019andriskfactorsforprolongedsarscov2infectioninlymphomapatientsmulticenterretrospectivecohortstudy AT hanmin 482longtermoutcomesofcoronavirusdisease2019andriskfactorsforprolongedsarscov2infectioninlymphomapatientsmulticenterretrospectivecohortstudy AT ahnsangmin 482longtermoutcomesofcoronavirusdisease2019andriskfactorsforprolongedsarscov2infectioninlymphomapatientsmulticenterretrospectivecohortstudy AT leeyongseop 482longtermoutcomesofcoronavirusdisease2019andriskfactorsforprolongedsarscov2infectioninlymphomapatientsmulticenterretrospectivecohortstudy AT yeomjoonsup 482longtermoutcomesofcoronavirusdisease2019andriskfactorsforprolongedsarscov2infectioninlymphomapatientsmulticenterretrospectivecohortstudy AT choijunyong 482longtermoutcomesofcoronavirusdisease2019andriskfactorsforprolongedsarscov2infectioninlymphomapatientsmulticenterretrospectivecohortstudy AT kunamsu 482longtermoutcomesofcoronavirusdisease2019andriskfactorsforprolongedsarscov2infectioninlymphomapatientsmulticenterretrospectivecohortstudy AT jeongsujin 482longtermoutcomesofcoronavirusdisease2019andriskfactorsforprolongedsarscov2infectioninlymphomapatientsmulticenterretrospectivecohortstudy AT kimjungho 482longtermoutcomesofcoronavirusdisease2019andriskfactorsforprolongedsarscov2infectioninlymphomapatientsmulticenterretrospectivecohortstudy AT kimjinseok 482longtermoutcomesofcoronavirusdisease2019andriskfactorsforprolongedsarscov2infectioninlymphomapatientsmulticenterretrospectivecohortstudy AT chunghaerim 482longtermoutcomesofcoronavirusdisease2019andriskfactorsforprolongedsarscov2infectioninlymphomapatientsmulticenterretrospectivecohortstudy AT chohyunsoo 482longtermoutcomesofcoronavirusdisease2019andriskfactorsforprolongedsarscov2infectioninlymphomapatientsmulticenterretrospectivecohortstudy AT kimyuri 482longtermoutcomesofcoronavirusdisease2019andriskfactorsforprolongedsarscov2infectioninlymphomapatientsmulticenterretrospectivecohortstudy AT ahnjinyoung 482longtermoutcomesofcoronavirusdisease2019andriskfactorsforprolongedsarscov2infectioninlymphomapatientsmulticenterretrospectivecohortstudy |